Results 151 to 160 of about 1,734 (194)

Maribavir: First Approval

Drugs, 2022
Maribavir (LIVTENCITYTM), a cytomegalovirus (CMV) enzyme pUL97 kinase inhibitor, is being developed by Takeda Pharmaceuticals for the treatment of CMV infections. Maribavir was recently approved in the USA for the treatment of post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir ...
openaire   +2 more sources

Maribavir (Livtencity)

Canadian Journal of Health Technologies, 2022
CADTH recommends that Livtencity should be reimbursed by public drug plans for the treatment of adults with post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to 1 or more prior antiviral therapies if certain conditions are met. Livtencity should only be covered to treat adult ...
openaire   +1 more source

New Perspectives on Antimicrobial Agents: Maribavir

Antimicrobial Agents and Chemotherapy, 2022
Maribavir was approved by the U.S. Food and Drug Administration in November 2021 for the treatment of adult and pediatric patients with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet.
Virginie Halpern-Cohen, Emily A. Blumberg   +1 more
openaire   +2 more sources

Maribavir (ViroPharma).

Current opinion in investigational drugs (London, England : 2000), 2005
ViroPharma, under license from GlaxoSmithKline, is developing maribavir, a DNA synthesis inhibitor for the potential prevention and treatment of human cytomegalovirus infections related to transplants (including solid organ and hematopoietic stem cells), congenital transmission, and in patients with HIV infection.
Henry, Lu, Sun, Thomas
openaire   +1 more source

Maribavir

Reactions Weekly
  +6 more sources

EFFICACY OF MARIBAVIR IN VALGANCICLOVIR-RESISTANT CYTOMEGALOVIRUS RETINITIS

RETINAL Cases & Brief Reports
Purpose: To determine whether maribavir is effective at treating ganciclovir-resistant cytomegalovirus retinitis. Methods: Retrospective case report of a lung-transplant patient with bilateral cytomegalovirus retinitis documented with serum and aqueous humor studies and color fundus
Jonathan C. Tsui, Vincent Huang, Anton M. Kolomeyer, Charles G. Miller, Aaron Mishkin, Albert M. Maguire   +5 more
openaire   +2 more sources

The current role of maribavir for treatment of cytomegalovirus in transplant recipients

Expert Opinion on Pharmacotherapy
Cytomegalovirus (CMV) is one of the most common infections after solid organ or hematopoietic stem cell transplantation. Typically, ganciclovir or valganciclovir have been used for first-line therapy, with foscarnet and cidofovir being used for resistant or refractory infections. Maribavir was recently approved as a novel CMV therapeutic for transplant
Maria, Vega Brizneda, Deepali, Boothankad Sharath, Thomas J, Rust, Zachary A, Yetmar   +3 more
openaire   +2 more sources

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial

Clinical Infectious Diseases, 2022
Robin Avery, sophie Alain, Emily A Blumberg   +2 more
exaly  

Maribavir use in patients with renal impairment

Transplant Infectious Disease, 2023
Alan Koff, Niyati Narsana, Muna Alnimri
openaire   +2 more sources

Maribavir versus investigator assigned therapy: Exploring the exploratory

Transplant Infectious Disease, 2023
Madeleine R. Heldman, Ajit P. Limaye
openaire   +2 more sources